Valneva SE VLA

VALNEVA Declaration of shares and voting rights Status as of August 31, 2026__________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 LyonRegulated market of Euronext Paris - Compartment B Declaration date: September 4, 2026 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Descri

In August 2026, Pfizer and BioNTech received U.S. FDA approval for their updated COMIRNATY COVID-19 vaccine targeting the XFG variant for high-risk individuals, while Pfizer and Valneva’s Lyme disease vaccine candidate PF-07307405 had its Marketing Authorization Application validated by the European Medicines Agency based on Phase 3 trial data. Together, these vaccine milestones highlight Pfizer’s ongoing role in infectious disease prevention across both seasonal COVID-19 protection and...